Explore every episode of the podcast AED | Audio Epilepsy Digest

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 22: The Epilepsy Follow-Up: Continue, Adjust, Switch—or Refer?

An adult outpatient special prompted by a nurse practitioner's request: three everyday visits, from breakthrough seizures to treatment burden and repeated medication trials. The August 2025 Xcopri liver-label update provides a concrete example of checking medication-specific safety requirements.

In this episode:
- Reassessing events, actual medication use and barriers before automatic escalation.
- Asking how a patient feels and functions, even when seizures have stopped.
- Reviewing adequacy of previous treatments and explaining comprehensive epilepsy referral.

Clinical context:
- Liver-warning symptoms include unexplained nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice or dark urine. Seek prompt clinical assessment. Early DRESS may occur without an evident rash.
- Xcopri labeling specifies baseline ALT, AST and total bilirubin unless available within three months. Follow-up testing is clinically indicated; no universal monthly schedule or liver-failure incidence is supplied.
- SANAD II studied newly diagnosed focal epilepsy, not switching stable patients or comparing cenobamate.
- Individualize emergency plans within local protocols and prescribing standards. NICE is UK guidance, not US regulation.
- Jehi’s surgical-referral consensus recommends offering evaluation up to age 70 and considering older patients without surgical contraindications. Comprehensive care remains individualized. Referral evaluates options and does not commit a patient to surgery.
- The label specifies ALT, AST and total bilirubin; other urgent tests are clinician-directed, not universal label requirements. Clinically indicated follow-up is broader than symptoms alone.

Sources:
- Xcopri US prescribing information, revised August 2025.
- NICE NG217, chapters 4, 7 and 10.
- Marson et al. SANAD II focal epilepsy. Lancet 2021. DOI: 10.1016/S0140-6736(21)00247-6.
- Jehi et al. Timing of referral for epilepsy surgery evaluation. Epilepsia 2022. DOI: 10.1111/epi.17350.

AED Quiz (non-accredited self-assessment):
https://audioepilepsydigest.com/episode-022-aed-quiz.html

AED website:
https://audioepilepsydigest.com/

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-022-ai-review.html

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 21: FCD: What Does the Diagnosis Actually Tell Us?

A monthly special on focal cortical dysplasia: what an integrated diagnosis explains, what anatomy and electrophysiology add, and where AI detection and targeted treatment remain uncertain.

Key takeaways:
- MRI impression, histopathology and molecular findings are connected but distinct. FCD type is not a severity ladder.
- Selected bottom-of-sulcus studies do not establish a universal resection rule.
- Mechanistic promise and exploratory subgroup signals do not establish a prescribing rule.

Editorial clarifications:
- MTOR variants were not detected in the available blood or saliva samples in Lim’s study; negative peripheral testing does not exclude brain-restricted mosaicism.
- Regional surgical-outcome differences are observational and may reflect surgical constraints; they are not individual predictions.
- No washout in the everolimus crossover trial allows potential carryover and limits interpretation. The trial did not demonstrate overall superiority.
- Independent AI testing evaluates performance under different conditions; detection is not a resection map.

Papers discussed:
- Najm et al. (2022). DOI: 10.1111/epi.17301
- Wagstyl et al. (2022). DOI: 10.1111/epi.17130; correction retained.
- Macdonald-Laurs et al. (2023). DOI: 10.1111/epi.17495
- Ripart et al. Corrected MELDGraph study; correction retained.
- Kaas et al. (2026). DOI: 10.1016/j.eplepsyres.2026.107778
- Lim et al. (2015). DOI: 10.1038/nm.3824
- Kim et al. (2025). DOI: 10.1002/epi4.13104

AED website:
https://audioepilepsydigest.com/

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-021-ai-review.html

Non-accredited AED Quiz:
https://audioepilepsydigest.com/episode-021-aed-quiz.html

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 20: Who Decides on Epilepsy Surgery?

From identifying people who have not reached evaluation to center-level recommendations and estimates of seizure benefit and visual harm, five papers examine how the path to epilepsy surgery is shaped—and what these studies cannot decide for an individual.

The opening welcomes Timon, the editor’s new Sheltie puppy, before the research discussion.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-020-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Caraway: recommendations varied across 29 pediatric centers after adjustment. A recommendation included invasive monitoring; it did not establish an operation, outcome, or inappropriate decision.
- Simmons: an EHR rule flagged possible cases for chart review. Among 84 confirmed cases of drug-resistant epilepsy, 48 had no evaluation initiated; the rule did not itself diagnose drug resistance.
- Coordinator tracking was associated with evaluation status. This observational finding establishes neither benefit nor lack of benefit from a coordinator intervention.
- Karpychev: MRI network measures showed an exploratory long-term outcome signal, with external AUC 0.65. The model is not a surgical exclusion rule or a resection map.
- Wreghitt: probabilistic tractography better delineated optic-radiation anatomy and estimated injury correlated with visual-field loss in 33 adults. It did not establish guaranteed safe margins or prevention of visual deficits.
- Englot supplies historical review-based referral context. Referral, recommendation, prediction, treatment, and patient preferences remain distinct decisions.

Editorial clarifications:
- Current ASM count or EHR medication exposure is not the same as adequately failed trials.
- In the MRI model, seizure freedom is the positive class; specificity 80% and NPV 63.9% concern non-seizure-free classification.
- The reflective closing question is commentary. The MRI paper is a disclosed one-day exception to the August 13–September 12 literature window.

Papers discussed:
- Caraway AR et al. Epilepsia (2026). PMID: 42621761.
- Englot DJ. Epilepsia (2026). PMID: 42611555.
- Simmons GB et al. Epilepsy & Behavior (2026). PMID: 42697047.
- Karpychev V et al. Neurology (2026). PMID: 42585607.
- Wreghitt S et al. Journal of Neurosurgery (2026). PMID: 42696783.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-020-ai-review.html

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 19: The Implantation Honeymoon—Who Gets the Credit: Implant, Stimulation, or Time?

When seizures change after intracranial electrodes are implanted but before stimulation begins, what can we actually attribute to the implant—and what remains time, sampling, treatment, or expectation?

The newest adult SEEG study leads this episode with results first. From there, we move from clinical seizure reports to scheduled RNS ECoG, rare no-stimulation observations, a disclosed single-center abstract from our own group, and an implanted-sham randomized trial. The evidence supports a real postimplant observation problem, not one proven mechanism or a universal treatment effect.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-019-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Roy-Chowdhury's adult SEEG cohort is a set of distinct last-follow-up groups, not one 51-patient longitudinal curve.
- The paper reports early responder and seizure-freedom counts, but its six-month denominator differs between the narrative and Table 1.
- Lane found a modest delay to first seizure during intracranial monitoring after adjustment for prior-day medication load; daily seizure frequency was not significantly reduced.
- Sun documented months of scheduled ECoG signal evolution after RNS implantation, an electrographic endpoint that does not establish clinical seizure benefit or one cause.
- Exceptional RNS and DBS observations show that changes can occur without active stimulation, but small samples and concurrent care prevent causal attribution.
- The editor's AES abstract suggests a predictive association, not proof that implantation caused later response or a validated biomarker.
- NAUTILUS compared active with sham stimulation on a shared implanted background. Its prespecified effectiveness endpoint was negative; later findings are supportive and cannot replace that endpoint.

Papers discussed:
- Roy-Chowdhury et al. Post-SEEG seizure-frequency study. Epilepsia. 2026. PMID: 42474247.
- Lane et al. Implantation effect during intracranial monitoring. Acta Neurol Scand. 2017. PMID: 27531652.
- Sun et al. Postimplant ECoG evolution in RNS. Clin Neurophysiol. 2018. PMID: 29233473.
- Thuberg et al. DBS insertional effect without stimulation. Neuromodulation. 2021. PMID: 33577139.
- Rumschlag et al. Extended RNS implantation-effect case. Epileptic Disord. 2024. PMID: 38787629.
- McCarthy and Burdette. RNS programming review. Neurotherapeutics. 2026. PMID: 42302539.
- Uysal et al. NAUTILUS randomized trial. Epilepsia. 2026. PMID: 42233958.

Editorial reference and disclosure:
- Rehim et al. “Does Honeymoon Lead to Happily Ever After? Single Center Experience with Implantation Effect in RNS Therapy.” AES Annual Meeting abstract 1.251. 2025. Erafat Rehim is the presenting author and AED editor. This author-involved, retrospective single-center abstract is treated as an unvalidated hypothesis, not independent confirmation.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-019-ai-review.html

Editorial review disclosure:
The final draft cleared two independent source-fidelity and clinical-safety reviews with minor listening notes. Earlier drafts were withheld for causal overstatement, endpoint confusion, unsupported mechanisms, or narrative imbalance. The clinician-editor completed listening QA and authorized release for Tuesday, September 1, 2026 at 7:00 AM EDT.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 18: How Safe Is Safe? The Long-Term Tradeoffs of Common Anti-Seizure Medications

When a patient asks, “You say Keppra is safe long term. Exactly how safe is it?”, the honest answer is not one lifetime percentage.

This episode separates years of clinical experience from years of structured observation, then compares levetiracetam, lamotrigine, and lacosamide across common burden, rare serious harm, cumulative toxicity, changing susceptibility, and seizure-control benefit. Long follow-up can be reassuring, but selected continuers are not the same denominator as everyone who starts treatment.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-018-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- “Safe long term” means a changing benefit-risk profile, not zero risk or a lifetime guarantee.
- Approval history gives decades of signal-detection experience; it does not provide a controlled lifetime denominator.
- Maximum structured observation reached beyond seven years for levetiracetam, six years for lamotrigine, and up to eight years for lacosamide in selected continuation cohorts.
- Levetiracetam's ongoing reassessment targets include mood or behavioral effects, fatigue, and renal-dose dependence.
- Lamotrigine's defining serious-rash risk is front-loaded during initiation and titration, while neurologic effects may persist or recur with dose or interaction changes.
- Lacosamide's dizziness and imbalance profile must be considered alongside conduction susceptibility, cardiac disease, and interacting drugs.
- Comparative tolerability depends on population, comparator, endpoint, and seizure-control benefit; this is not a universal drug ranking.

Papers discussed:
- Marson et al. SANAD II focal-epilepsy trial. Lancet. 2021. PMID: 33838757.
- Fröling et al. Levetiracetam/brivaracetam adverse-event meta-analysis. 2026. PMID: 41824075.
- Depondt et al. Long-term levetiracetam retention. JNNP. 2006. PMID: 16361605.
- Bauer et al. Long-term levetiracetam follow-up. 2006. PMID: 16911344.
- Faught et al. Six-year lamotrigine continuation. 2004. PMID: 14751204.
- Li et al. Three-year real-world LTG-LEV comparison. 2020. PMID: 32679487.
- Ben-Menachem et al. Lacosamide versus carbamazepine-CR extension. Epilepsia. 2019. PMID: 31755090.
- Rosenfeld et al. Lacosamide extension up to eight years. 2014. PMID: 25461210.
- Buoso et al. Antiseizure medications and bone health. 2024. PMID: 40530090.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-018-ai-review.html

Editorial disclosure:
The final fifth draft cleared two independent source-fidelity and clinical-safety reviews with minor notes. Earlier expanded drafts were withheld for causal overstatement, an incorrect study attribution, loss of the direct Keppra question, and unsupported conversion of heterogeneous bone-health evidence into individual risk and treatment advice. The clinician-editor completed listening QA and authorized release for Monday at 7:00 AM EDT.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 17: What Counts as Neuromodulation Success?

Should the 50% responder rate remain the primary definition of neuromodulation success?

This episode stages the strongest case for a simple common benchmark against the strongest case for a multidimensional clinical verdict. VNS, pediatric thalamic DBS and RNS, long-term RNS, ESTEL, CONNECTiVOS, PuLsE, and two biomarker studies are used to test what the threshold captures—and what it hides.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-017-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Keep the 50% responder rate as a standardized anchor, but never let it stand alone.
- Pair any threshold with the underlying reduction distribution, seizure freedom, denominator, and time horizon.
- Similar 12-month responder proportions do not prove similar early experience or device superiority.
- Quality of life, harms, and treatment burden are core counseling domains rather than decorative secondary outcomes.
- ESTEL preserved a negative diary primary comparison alongside a positive secondary ambulatory-EEG responder signal; objective detection and patient importance are not synonyms.
- A high AUC in a tiny held-out split or a post-treatment blood-marker association is hypothesis-generating, not a patient-selection tool.

Papers discussed:
- Zhao et al. Vagus nerve stimulation as an add-on therapy in patients with epilepsy. Acta Epileptologica. 2026. doi:10.1186/s42494-026-00272-4.
- Tenhoeve et al. Comparative multicenter evaluation of thalamic neuromodulation for treatment-resistant epilepsy in children. Epilepsia. 2026. doi:10.1002/epi.70402.
- Zhou et al. Nonlinear neurodynamics of N2 sleep EEG predict outcomes of ANT-DBS in epilepsy. Journal of Neural Engineering. 2026. doi:10.1088/1741-2552/ae94b2.
- Tang et al. Peripheral blood inflammatory biomarkers and response to VNS in pediatric drug-resistant epilepsy. European Journal of Pediatrics. 2026. doi:10.1007/s00431-026-07256-z.
- Niazi et al. What defines response to VNS in children with drug-resistant epilepsy? Epilepsia. 2025. doi:10.1111/epi.18520.
- Dalic et al. DBS of Thalamic Centromedian Nucleus for Lennox-Gastaut Syndrome (ESTEL Trial). Annals of Neurology. 2022. doi:10.1002/ana.26280.
- Nair et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020. doi:10.1212/WNL.0000000000010154.
- Ryvlin et al. The long-term effect of VNS on quality of life: The PuLsE trial. Epilepsia. 2014. doi:10.1111/epi.12611.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-017-ai-review.html

Editorial disclosure:
Two independent AI-assisted reviews cleared the final candidate with minor notes and no blocking source-fidelity or clinical-safety finding. The first draft was withheld after it confused an electrographic responder proportion with seizure-reduction magnitude and described interval seizure freedom as cure. The corrected final draft preserves endpoint hierarchy, denominators, design limits, and the research-stage status of proposed biomarkers. The clinician-editor authorized shipment for Monday at 7:00 AM EDT.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 16: Signals, Silence, and Zero Events

What can an observational association, the absence of a consistent reported pattern, and zero observed events actually justify in medication counseling?

This episode compares three very different medication-safety evidence systems: a nationwide prenatal antiseizure-medication cohort, a global eslicarbazepine pregnancy safety database, and a small selected cohort restarting cenobamate after short interruptions. The practical method is simple: identify the denominator, comparator, missingness, exposure measurement, outcome ascertainment, and selection process before translating any memorable conclusion into care.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-016-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- The Korean cohort found adjusted associations with selected neurodevelopmental outcomes; it did not establish a causal medication effect.
- Only 48.2% of exposed mothers in that cohort had epilepsy, so indication, disease severity, familial factors, and prescription-based exposure remain central limitations.
- The eslicarbazepine database collected reports across miscarriage, congenital anomaly, neonatal adverse effect, and premature birth, but substantial missingness and the lack of a valid denominator or comparator prevent incidence and comparative-risk claims.
- Zero attributed hypersensitivity events among 32 previously tolerant cenobamate patients is reassuring within that selected setting, but an approximate upper uncertainty bound remains near 9%.
- Residual drug exposure is a proposed pharmacokinetic explanation, not proof of immune tolerance or authorization for a universal maintenance-dose restart protocol.

Papers discussed:
- Kim et al. Prenatal exposure to Antiseizure Medications for all indications and the risk of neurodevelopmental disorders in offspring. Seizure. 2026. doi:10.1016/j.seizure.2026.05.030.
- Lopes et al. Pregnancy outcomes following Eslicarbazepine acetate exposure in women with epilepsy. Seizure. 2026. doi:10.1016/j.seizure.2026.05.027.
- Feldman et al. Hypersensitivity reaction risk when restarting cenobamate after discontinuation. Epilepsia Open. 2026. doi:10.1002/epi4.70288.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-016-ai-review.html

Editorial disclosure:
Two independent AI-assisted reviews cleared the final candidate with minor notes and no blocking source-fidelity or clinical-safety finding. The remaining notes concerned prior-rash-history wording, complete reporting of pregnancy outcome categories, pronunciation of selected technical terms, separation of two rash observations, and maintaining the restart mechanism as a hypothesis. The clinician-editor listened to and approved the release candidate.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 15: Fellow Bootcamp: OSA Is Not Just a Comorbidity

When should obstructive sleep apnea be treated as more than a passive comorbidity in epilepsy care?

This special uses the nine Bradford Hill viewpoints to examine whether OSA may modify epilepsy outcomes. The hosts keep three evidence lanes separate: seizure and interictal-discharge burden, incident or late-onset epilepsy, and surrogate SUDEP-risk markers. They also examine what the current CPAP studies can—and cannot—support.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-015-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Bradford Hill viewpoints organize causal reasoning; they are not a checklist, vote, or proof score.
- OSA is commonly reported in people with epilepsy, but prevalence estimates are heterogeneous and do not establish causation.
- Prospective and claims-based studies support an incident-epilepsy and late-onset-epilepsy hypothesis, with residual confounding and exposure measurement still important.
- Associations with revised SUDEP risk scores concern surrogate markers, not observed SUDEP events or evidence of prevention.
- Treat confirmed OSA for established sleep-medicine indications and track epilepsy outcomes without promising an epilepsy-specific response.

Sources include Rehim, Vendrame, and Devinsky 2026; Lin et al. 2017; Harnod et al. 2017; Carosella et al. 2023; Soontornpun et al. 2024; Pornsriniyom et al. 2014; Malow et al. 2008; and McCarter et al. 2018.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-015-ai-review.html

Editorial disclosure:
Two independent AI-assisted reviews cleared the episode with minor notes and no blocking source-fidelity or clinical-safety finding. Minor notes concern a few contextual certainty words, process-like language near the opening, an over-categorical effect-size heuristic, the ARIC sleep-substudy denominator, and author-name pronunciation. The clinician-editor listened to and approved the release candidate.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 14: Fellow Bootcamp: From EMU to SEEG to Surgery

How should an epilepsy fellow turn EMU findings, imaging, neuropsychology, and other phase 1 data into a defensible surgical hypothesis?

This special reviews the cortical concepts used in presurgical reasoning, how phase 1 findings become a testable hypothesis, when stereoelectroencephalography may resolve an actionable uncertainty, the limitations of sparse intracranial sampling, and how teams orient among resection, ablation, disconnection, neuromodulation, or no procedure.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-014-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

Key takeaways:
- Phase 1 evaluation should build a coherent electroclinical hypothesis and expose meaningful contradictions.
- Symptomatogenic, irritative, seizure-onset, epileptogenic-lesion, functional-deficit, eloquent-cortex, and epileptogenic zones may overlap but are not interchangeable.
- A visible lesion can strengthen a hypothesis but does not independently establish causality.
- S-E-E-G is spatially limited sampling and is most useful when it tests bounded alternatives that could change treatment.
- Treatment choice integrates targetability, network distribution, functional risk, expected benefit, residual uncertainty, and patient goals.

Sources include Schuele et al. 2025, Jayakar et al. 2016, Miller and Fine 2022, Simpson et al. 2022, and Jehi et al. 2022.

AI-assisted editorial/source review:
https://audioepilepsydigest.com/episode-014-ai-review.html

Editorial disclosure:
The clinician-editor selected this audio through an explicit human override after two independent AI-assisted reviews advised targeted revision. The central framework was substantially grounded, while some examples and mechanisms remain teaching simplifications. The final AI passage is intentionally speculative and does not describe current clinical capability.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 13: Temporal Encephaloceles: Lesion, Network, and How Much to Resect?

This monthly special debate asks how epilepsy surgery teams should reason about temporal encephaloceles: as a leading surgical target, as a clue to broader temporal network involvement, or both.

The episode uses surgical series, systematic reviews, imaging studies, EEG source-localization work, and a direct sEEG case to frame a conference-style question: when is a tailored mesial-sparing approach reasonable, and when should discordant data prompt broader mapping or a wider surgical hypothesis?

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-013-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-013-ai-review.html

Key takeaways:
- Temporal encephaloceles can be missed on routine review and may require deliberate skull-base re-review or additional imaging.
- Finding a temporal encephalocele is not the same as proving seizure onset from the herniated tissue.
- Concordant imaging, semiology, EEG, PET, neuropsychology, and invasive recordings can support a lesion-centered hypothesis in selected cases.
- Surgical extent should follow the full presurgical picture, not a default rule for or against hippocampectomy.
- The evidence base is mainly retrospective and selected, so the episode frames conference reasoning rather than a guideline.

Papers discussed include Smith 2023, Tsalouchidou 2025, Khoudari 2025, Zhou 2024, Garcia-Gracia 2024, Kondylis 2026, Ortiz 2025, Tsalouchidou 2023, Cox 2024, and Agashe 2023.

Caveats:
- Temporal encephaloceles are treated as potentially important surgical clues, not automatic proof of epileptogenicity.
- MRI metrics, PET patterns, CT defects, and postprocessing are supportive data, not direct proof of seizure onset.
- The direct sEEG case is illustrative and should not be generalized beyond a selected single-patient report.
- The practical framework is intended as conference reasoning, not a rigid surgical algorithm.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 12: Care Pathways Shape Epilepsy Outcomes

This weekly recent-studies episode asks what happens when epilepsy outcomes are shaped not only by medications, procedures, or devices, but by the care pathway around the patient.

The episode follows five care-delivery signals: rural inpatient outcomes, inpatient video-EEG access after repeated seizure-related emergency visits, pediatric-to-adult transition, brain tumor-related epilepsy coordination, and a UK roadmap for technology-enabled service redesign.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-012-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-012-ai-review.html

Key takeaways:
- Care pathways are measurable parts of epilepsy care, not just background logistics.
- Rural-urban inpatient differences, vEEG access, transition care, and tumor-epilepsy coordination all point to pathway-level gaps.
- The studies are mostly observational or service-mapping work, so they support careful questions rather than practice-changing mandates.
- Technology can support redesign, but the roadmap source is not proof that specific digital tools improve outcomes.
- Repeated ED visits, transition handoffs, and multidisciplinary tumor care are moments to ask whether the patient reached the right diagnostic and longitudinal services.

Papers discussed include:
1. Rural-urban disparities in epilepsy hospitalizations in the United States. PMID: 42234954. PMCID: PMC13239426.
2. Kozak et al. Access to inpatient video-EEG monitoring for patients with frequent seizure-related emergency visits. Epilepsy Research (2026). PMID: 42349236.
3. Modi et al. Measuring transition success from paediatric to adult epilepsy services and its association with seizure outcomes. Archives of Disease in Childhood (2026). PMID: 42082329.
4. Anghileri et al. Mapping integrated care for brain tumour-related epilepsy in the Italian RIN-IRCCS network. Neurological Sciences (2026). PMID: 42350833. PMCID: PMC13303563.
5. Terry and Shankar. The future of epilepsy care in the United Kingdom: A roadmap for technology-enabled transformation. Epilepsia Open (2026). PMID: 41964582. PMCID: PMC13238867.

Caveats:
- Rurality, vEEG access, transition success, and pathway gaps are discussed as associations or service-design signals, not causal proof.
- Private-insurance examples in the audio should be heard as illustrative possibilities, not findings directly tested by the rural-urban study.
- The wearable false-alarm scenario is a hypothetical service-design concern, not an observed outcome in the technology-roadmap paper.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 11: Signals Before Practice Change: GLP-1 Drugs and the Temptation to Overread

This weekly recent-studies episode asks how epileptologists should talk about exciting signals before they become practice-changing evidence.

The main thread is GLP-1 receptor agonists and seizure-related outcomes in diabetes-linked populations, with pediatric levetiracetam and VNS predictor studies used as comparator examples of evidence restraint.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-011-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-011-ai-review.html

Key takeaways:
- GLP-1 findings are hypothesis-generating signals, not seizure-treatment evidence.
- AbuAlrob et al. reported HR 0.82 for EHR-coded seizure recurrence; this is best described as an estimated 18% lower hazard with about a 2.1 percentage-point absolute recurrence difference.
- Pediatric levetiracetam is useful, but active-comparator evidence does not prove automatic superiority.
- VNS prognostic factors are research signals, not deterministic implantation rules.
- Clinical language matters when patient expectations can outpace the evidence.

Papers discussed include:
1. Eun Y, Bong S, et al. Semaglutide and adult-onset seizure target-trial emulation. Neurology (2026). PMID: 42308439.
2. Sindhu U, et al. Newer glucose-lowering drugs and late-onset seizure/epilepsy meta-analysis. Epilepsia Open (2024). PMID: 39487832.
3. AbuAlrob MA, et al. GLP-1 receptor agonist initiation and seizure recurrence in adults with epilepsy. Epilepsia (2025). PMID: 41251033.
4. Balestrini S, et al. Pediatric levetiracetam systematic review and meta-analysis. Neurology (2026). PMID: 42202238.
5. VNS prognostic-factor systematic review and meta-analysis. Neurosurgical Review (2026). PMID: 42307795.
6. Crutcher R, et al. VNS response predictors retrospective cohort. Neurosurgical Review (2025). PMID: 41042470.

Caveats:
- These GLP-1 data do not support prescribing for seizure control.
- Cardiovascular and renal outcome trials were not epilepsy-prevention trials.
- EHR-coded seizure recurrence is not seizure-diary adjudication.
- Crutcher et al. should not be turned into a 5-year VNS window rule.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 10: A Positive Signal With a Negative Primary Endpoint: The NAUTILUS Trial

This monthly special is a journal-club reading of NAUTILUS, the randomized sham-controlled trial of responsive centromedian thalamic stimulation for drug-resistant idiopathic generalized epilepsy with recurrent generalized tonic-clonic seizures.

The episode's main point is endpoint discipline: the primary safety endpoint was met, the prespecified primary effectiveness endpoint was not statistically significant, and the longer-term and post hoc signals remain clinically important but bounded.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-010-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-010-ai-review.html

Key takeaways:
- NAUTILUS is best read as an encouraging signal, not a simple positive trial.
- The prespecified time-to-second-GTCS effectiveness endpoint was not statistically significant.
- Post hoc and 18-month seizure outcomes may still matter clinically, but they cannot erase the endpoint hierarchy.
- The narrow practice implication is a serious counseling and referral discussion for carefully selected drug-resistant IGE patients with recurrent GTCS.
- Thalamic RNS for IGE should not be framed as established standard-of-care therapy from this trial alone.

Papers discussed include:
1. Uysal et al. NAUTILUS randomized controlled trial, Epilepsia (2026). PMID: 42233958.
2. Haneef and Skrehot. Neurostimulation in generalized epilepsy, Epilepsia (2023). PMID: 36727550.
3. Alhourani et al. Bilateral centromedian thalamic neuromodulation systematic review and IPD meta-analysis, Neuromodulation (2026). PMID: 40498441.
4. Sisterson et al. Centromedian thalamic RNS in IGE case series, Journal of Neurology, Neurosurgery & Psychiatry (2022). PMID: 35217517.
5. Nanda et al. Centromedian-region thalamic RNS in IGE and multifocal epilepsy, Epilepsia (2024). PMID: 39052021.

Caveats:
- The Nanda 2024 82.6% average seizure reduction applies to the 17 patients with at least 1 year of follow-up, not all 21 implanted patients.
- NAUTILUS post hoc and 18-month outcomes are encouraging but cannot rescue the negative prespecified primary effectiveness endpoint.
- Centromedian thalamus should be understood as a plausible thalamocortical network node, not a proven circuit breaker.
- The episode supports careful discussion and referral consideration, not a guideline-level recommendation.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 9: From Paper to Podcast: The AED Assembly Line

This special episode explains how Audio Epilepsy Digest is made. Instead of covering a new set of epilepsy papers, it opens the production process itself: how sources enter the packet, how the episode angle is chosen, how AI helps create a conversational draft, how the transcript is checked, and where human editorial responsibility remains.

The central point is modest: useful AI in medicine does not have to mean diagnosis or prescribing. In AED, the goal is to help clinicians learn, organize evidence, and arrive at clinic better prepared, while keeping the human editor responsible for framing, caveats, and release.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-009-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-009-ai-review.html

Key takeaways:
- AED starts from source material and a clinician-framed question, not from audio generation.
- AI can help draft, converse, transcribe, extract claims, and red-team a candidate, but it does not own clinical judgment.
- Transcript-first review helps make fluent audio auditable.
- Public source-review pages and listener feedback are part of AED's transparency loop.
- This episode is a process transparency special, not proof that the workflow has been externally validated.

Source review note:
This episode went through AI-assisted editorial review before release staging. The AI review recommended regeneration for process and branding issues in the spoken audio, including the exact closing language. Erafat listened to the candidate and explicitly cleared this version for release staging by human override.

Caveats:
- AI-assisted source review is not independent peer review.
- The episode describes AED's own documented process; it does not validate AED as a general medical education intervention.
- The public review page records the AI-review caveats and the human override decision.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 8: Status Epilepticus in Critical Care

This weekly recent-studies episode uses papers from roughly the last month, plus ESETT as landmark context, to ask what happens when status epilepticus moves beyond the emergency algorithm and becomes a critical-care problem.

The episode covers ICU practice variation, point-of-care AI seizure burden, perfusion imaging for seizure-vs-stroke-mimic uncertainty, VNS for SRSE/NORSE, and emergency resection in selected lesional SRSE.

The practical message is evidence-tier discipline: name the kind of evidence before naming the intervention.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-008-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-008-ai-review.html

Key takeaways:
- ESETT anchors one second-line convulsive status decision point, but not ICU/SRSE/NORSE salvage care.
- ICU status epilepticus care is shaped by cEEG access, training, and workflow limits.
- Point-of-care AI seizure burden is a risk signal associated with discharge outcome, not proof that AI-guided treatment improves outcomes.
- Perfusion imaging can add context in selected cases, but EEG remains central.
- VNS and emergency resection remain salvage conversations with strict evidence boundaries.

Papers discussed include:
1. Kapur J, et al. "Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus." New England Journal of Medicine (2019). PMID: 31774955.
2. Fanet et al. "Assessment of therapeutic management practices in generalized and focal motor status epilepticus." Journal of Intensive Medicine (2026).
3. Parvizi J, et al. "Point-of-Care Artificial Intelligence Measure of Seizure Burden Associates With Clinical Outcome at Discharge." Critical Care Medicine (2026). PMID: 42223304.
4. "Brain perfusion imaging in patients with status epilepticus, seizures, and IIC patterns." Clinical Neurophysiology Practice (2026).
5. Yoo JY, et al. "Vagus nerve stimulation as an adjunctive therapy for super-refractory status epilepticus including NORSE." Epilepsy & Behavior (2026). PMID: 41875755.
6. "Surgical resection as salvage therapy for super-refractory status epilepticus." Epilepsy & Behavior Reports (2026).

Caveats:
- ESETT should not be generalized to nonconvulsive, NORSE, SRSE, neuromodulation, or surgical salvage decisions.
- Survey data do not define an optimal ICU protocol.
- AI seizure burden is associative and does not replace expert EEG interpretation.
- Perfusion imaging is an adjunct, not a standalone diagnostic test.
- VNS and emergency resection evidence is not generalizable routine care.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 7: Real-World Evidence Meets Surgical Assumptions

This weekly recent-studies episode uses papers published in roughly the last month to ask how epileptologists should counsel patients with drug-resistant focal epilepsy when new evidence strengthens some assumptions, weakens others, and warns against turning plausible anatomy or AI output into shortcuts.

The episode covers real-world RNS postapproval outcomes, polymicrogyria epilepsy surgery, piriform cortex resection validation, and large-language-model diagnostic reasoning from seizure narratives.

The practical message is restrained: outcome data, visible lesions, anatomical targets, and AI models can all be useful, but each answers a different question. Surgical counseling should stay grounded in evidence quality, individualized mapping, and expert review.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-007-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-007-ai-review.html

Key takeaways:
- RNS postapproval data strengthen confidence in long-term palliative neuromodulation for selected adults with focal epilepsy, but they do not define universal treatment sequencing.
- PMG-related epilepsy can be surgically treatable in selected patients, but the visible malformation is not automatically the full epileptogenic zone.
- A 2026 validation study found no association between connectivity-defined piriform cortex resection and seizure freedom, arguing against routine targeting while preserving patient-specific network evaluation.
- LLMs can organize seizure-semiology information above chance in a benchmark task, but reasoning and citation errors keep them in the decision-support category.

Papers discussed include:
1. Eliashiv D, et al. "Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy." Neurology (2026). PMID: 42030518.
2. Rinella K, et al. "Efficacy of neurosurgical interventions for epilepsy in polymicrogyria." Epilepsia Open (2026). PMID: 41689720.
3. "No link between piriform cortex subregion resection and seizure freedom in two cohorts with temporal lobe epilepsy." Journal of Neurology (2026). PMID: 42174251.
4. Poon MTC, et al. "Evaluating large language models for diagnostic reasoning from unstructured clinical narratives in epilepsy." Communications Medicine (2026). PMID: 42174195.

Source review note:
This episode went through AED's automatic two-reviewer source review. The final regenerated candidate cleared both reviewers with minor notes before human audio QA.

Caveats:
- RNS findings are noncomparative postapproval outcomes, not proof that neuromodulation should bypass resection or ablation evaluation.
- PMG surgery evidence is heterogeneous and does not make the visible lesion a universal target.
- The piriform cortex result is a negative routine-targeting validation, not proof that piriform involvement never matters.
- LLM benchmark performance is not clinical authorization for delegated surgical localization or triage.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 6: From Random Seizures to Risk States

This monthly special asks whether seizure timing is moving from clinical randomness toward individualized, time-varying risk states.

The episode covers recent work on epilepsy chronobiology, seizure cycles, past-only forecasting pipelines, chance-model pitfalls, diary and wearable approaches, home EEG feasibility, sleep-drive physiology, and computational medication-timing models.

The practical message is restrained: seizure timing is becoming a serious clinical-research variable, but current evidence supports better questions and better trials more than routine patient-facing forecasts or medication-timing changes.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-006-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-006-ai-review.html

Key takeaways:
- Seizure timing can reflect circadian, sleep-wake, sleep-drive, and multidien risk rhythms, but that does not make seizures reliably predictable for routine care.
- Forecasting claims need past-only implementation, meaningful chance models, simple benchmarks, prospective validation, and attention to false alarms and patient burden.
- Wearable, diary, and home EEG studies show why the field is plausible, but feasibility and proof of principle are not the same as clinical effectiveness.
- Medication-timing models and sleep-drive experiments are useful for hypothesis generation, not patient-specific treatment advice.

Papers discussed include:
1. Baud MO, et al. "Timing is everything: Expert opinion on researching epilepsy rhythms by the ILAE Task Force on Chronobiology." Epilepsia (2026). PMID: 41483455.
2. Yang H, et al. "Seizure forecasting with epilepsy cycles: On the causality of forecasting pipelines." Epilepsia (2026). PMID: 41591752.
3. Andrzejak RG, et al. "Are seizure forecasts and cycles better than chance? What chance?" Epilepsia (2026). PMID: 41783988.
4. Chang CY, et al. "Rigorous evaluation of five models for e-diary-only seizure forecasting-retrospective and prospective datasets do not outperform the Napkin method." Epilepsia (2026). PMID: 41085335.
5. Xiong W, et al. "Forecasting seizure likelihood from cycles of self-reported events and heart rate: a prospective pilot study." eBioMedicine (2023). PMID: 37331164.
6. Cuddapah VA, et al. "Sleep drive, not total sleep amount, increases seizure risk." Nature Communications (2025). PMID: 40730814.

Source review note:
This episode went through AED's automatic two-reviewer source review. Both reviewers cleared the episode with minor caveats before human audio QA.

Caveats:
- Forecasting remains probabilistic and research-stage.
- The sleep-drive source is preclinical and should not be treated as human sleep advice.
- Medication-timing modeling is not a recommendation to change antiseizure medication schedules.
- Home EEG feasibility and forecasting protocols do not yet prove clinical effectiveness.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 5: Cognition Is Becoming Actionable

Are recent studies moving epilepsy cognition from a recognized comorbidity to a measurable and partly modifiable care target?

This episode of Audio Epilepsy Digest looks at four recent Neurology and Epilepsia papers on sleep, cognitive phenotyping, psychosocial rehabilitation, and dementia-plus-epilepsy medication safety.

The practical message is cautious but useful: cognition in epilepsy is becoming easier to measure and partly more actionable, but the evidence does not prove that sleep treatment prevents dementia or that rehabilitation restores objective memory.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-005-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-005-ai-review.html

Key takeaways:
- In focal epilepsy, nonoptimal self-reported sleep was associated with worse executive function and higher dementia-risk signal, but causality remains unproven.
- IC-CoDE is research infrastructure for reproducible cognitive phenotyping, not a clinical decision tool.
- Cognitive and psychosocial rehabilitation improved quality of life and anxiety more clearly than objective delayed recall.
- In dementia plus epilepsy, first ASM survival associations are clinically important but still registry-based and vulnerable to residual confounding.

Papers discussed:
1. Tai XY, et al. "The Relationship Between Sleep, Cognition, and Dementia Risk in People With Focal Epilepsy." Neurology (2026). PMID: 42018962.
2. Brunger T, et al. "The International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) Portal: An open source resource for neuropsychological research in epilepsy." Epilepsia (2026). PMID: 42095829.
3. Mameniskiene R, et al. "Rehabilitation of cognition and psychosocial well-being in epilepsy: Results of a randomized waiting list-controlled trial." Epilepsia (2026). PMID: 41984512.
4. Zelano J, et al. "Differences in Survival Associated With the First Antiseizure Medication in People With Dementia and Epilepsy." Neurology (2026). PMID: 41996657.

Source review note:
This episode went through AED's automatic two-reviewer source review. Both reviewers cleared the episode with minor caveats before human audio QA.

Caveats:
- Sleep duration in Tai et al. was self-reported and observational.
- IC-CoDE should not be used for individual clinical decision-making.
- The rehabilitation trial supports patient-reported benefit more strongly than objective cognitive improvement.
- Zelano et al. should be read as association, not causal ASM ranking.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 4: Drug-Resistant Epilepsy in 2026

Does the pathway after two failed antiseizure medications still end in surgery?

This episode of Audio Epilepsy Digest looks at the 2026 drug-resistant epilepsy treatment pathway through cenobamate surgery-timing data, the FRANCE anterior thalamic DBS trial, and emerging intracranial biomarker work.

The practical message is coexistence, not replacement. Cenobamate may change timing for selected patients, surgical evaluation still matters when a structural target is plausible, ANT-DBS remains palliative rather than curative, and biomarkers are promising research tools rather than current pathway arbiters.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-004-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://audioepilepsydigest.com/

AI editorial/source review for this episode:
https://audioepilepsydigest.com/episode-004-ai-review.html

Key takeaways:
- Pellinen's cenobamate findings are a single-center association in a selected subgroup, not proof that medication replaces surgery.
- Kerr and McFarlane frame the key distinction: surgical delay is not the same as surgical obviation.
- FRANCE suggests potential benefit for ANT-DBS in a highly refractory VNS-failed cohort, but it did not prove superiority over best medical therapy.
- Aiello's ANT spectral biomarkers are hypothesis-generating and require prospective validation before clinical programming use.

Papers discussed:
1. Pellinen J, et al. "Delayed and deferred surgery associated with cenobamate use in people with drug-resistant focal epilepsy." Epilepsia (2026). PMID: 41885758.
2. Kerr WT, McFarlane KN. "Redefining the treatment pathway for medication-resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay." Epilepsia (2026). PMID: 41972812.
3. Chabardes S, et al. "Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial." Epilepsia (2026). PMID: 41902639.
4. Aiello G, et al. "Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study." Brain (2026). PMID: 41934257.

Source review note:
This episode went through AED's automatic two-reviewer source review and regeneration loop. Earlier drafts were rejected or revised before this version cleared with minor caveats.

Caveats:
- Disparity mechanisms discussed around surgical timing should be understood as hypotheses, not findings directly tested by Pellinen.
- Quality of life in FRANCE is multifactorial; palliative seizure-burden reduction should not be treated as equivalent to seizure freedom.
- Cenobamate claims should remain anchored to Pellinen's selected subgroup and single-center retrospective design.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Episode 3: Epilepsy Care Beyond the Seizure Count

What should epilepsy care measure when seizure counts are not enough?

This episode of Audio Epilepsy Digest looks at four recent epilepsy papers that widen the frame beyond seizure frequency. The studies move across respiratory physiology, at-home EEG monitoring, patient-facing seizure terminology, and the lived burden of epilepsy for patients and caregivers.

The common thread is measurement humility. Seizure counts remain essential, but they do not capture the whole clinical problem. Better epilepsy measurement will need to integrate physiology, cognition and consciousness, real-world monitoring, patient-reported burden, and caregiver effects while staying honest about what is still research-grade rather than practice-changing.

AED Quiz for this episode:
https://audioepilepsydigest.com/episode-003-aed-quiz.html

Listen and follow Audio Epilepsy Digest:
https://erafat.github.io/audio-epilepsy-digest/

AI editorial/source review for this episode:
https://erafat.github.io/audio-epilepsy-digest/episode-003-ai-review.html

Key takeaways:
- Respiratory physiology may become an important risk-signal domain, but the current respiratory-variability study should not be heard as a validated individual SUDEP prediction tool.
- At-home EEG self-monitoring appears feasible for selected, supported patients, but it does not replace routine EEG, ambulatory EEG, EMU evaluation, or expert interpretation.
- Patient-facing definitions of ictal impairment of consciousness can be understandable, but terminology comprehension is not the same as proof of improved clinical outcomes.
- Patient-burden research reinforces that seizure counts miss mood symptoms, fatigue, sleep disruption, productivity effects, and caregiver burden, while the current survey remains selected and descriptive.

Papers discussed:
1. Caplan R, et al. "Association of Interictal Respiratory Variability and Severity of Postictal Hypoxemia After Generalized Convulsive Seizures." Neurology (2026). PMID: 41805401. PMCID: PMC13034677.
2. Cousyn L, et al. "Out of the lab, into real life: Evaluating at-home EEG self-monitoring." Epilepsia Open (2026). PMID: 41701004. PMCID: PMC13052238.
3. Marcinski Nascimento D, et al. "Persons with epilepsy and their caregivers understand the definition of ictal impairment of consciousness." Epilepsia (2026). PMID: 41705916. PMCID: PMC13075620.
4. Wagner S, et al. "What does it mean to live with epilepsy? Burden of illness from the patient perspective." Epilepsia Open (2026). PMID: 41770623. PMCID: PMC13052003.

Source review note:
This episode went through AED's transcript-first AI-assisted source review process. The generated audio was transcribed, checked against the full-text source packet, and forced through a pass/revise/regenerate gate. Two earlier audio candidates were rejected before this version cleared AI source review with minor caveats and then passed human audio QA.

Caveats:
- The respiratory paper supports association and biomarker potential, not individual-level SUDEP prediction.
- The home EEG paper supports feasibility in selected, supported patients, not replacement of standard clinical EEG workflows.
- The terminology paper supports comprehension of a proposed definition, not downstream outcome improvement.
- The burden-of-illness paper is descriptive and selected. PHQ-9 and GAD-7 findings are screening results, not formal diagnoses, and the survey does not establish treatment status, mechanism, or medication causality.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

What changes in epilepsy care when we widen the lens beyond raw seizure counts?

This episode of Audio Epilepsy Digest looks at four blind spots that appear when epilepsy care is organized too narrowly around seizure counts: etiologic workup after pediatric status epilepticus, early cognitive burden in newly diagnosed focal epilepsy, drug-specific dose logic in idiopathic generalized epilepsy, and the outcome measures used to judge rescue therapy in seizure clusters.

The through-line is simple: the right clinical question changes with the problem in front of us. Sometimes the missed issue is genetics. Sometimes it is four-week verbal retention rather than 30-minute recall. Sometimes it is whether escalating lamotrigine is still doing useful work. And sometimes it is whether a rescue medication should be judged by chronic seizure freedom or by the interval between treated clusters.

Topics covered:
- when pediatric status epilepticus should prompt a stronger genetics-first lens
- what the accelerated long-term forgetting paper actually shows, and what it does not, about early memory burden
- why ASM dose-response should remain drug-specific rather than assumed to be uniform
- why the diazepam nasal spray SEIVAL paper matters more for endpoint design and counseling than for immediate prescribing

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.

Should thalamic sEEG sampling be standard of care, selectively hypothesis-driven, or research-only?

This first Audio Epilepsy Digest release takes up the February 2026 Brain debate cluster on thalamic stereoEEG and focuses on what actually matters for epileptologists at academic centers: SEEG planning, neuromodulation targeting, safety, ethics, and institutional policy.

In this episode, the hosts examine:
- whether thalamic sampling changes real clinical decision-making
- when thalamic signals may be justified in hypothesis-driven intracranial exploration
- how the argument shifts when neuromodulation planning is part of the goal
- where the current literature reflects expert interpretation more than settled comparative outcomes evidence

This is a source-grounded special episode built from a tightly related editorial-plus-opinions packet, so the goal is not to force false consensus. The takeaway is a practical policy conversation for current practice, with explicit attention to what remains uncertain.